Short-Term Outcomes of Total Hip Arthroplasty after Liver Transplantation

Akihito Oya, MD, PhD, Taro Umezu, MD, Ryo Ogawa, MD, Toru Nishiwaki, MD, PhD, Yasuo Niki, MD, PhD, Masaya Nakamura, MD, PhD, Morio Matsumoto, MD, PhD, Arihiko Kanaji, MD, PhD

Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan

Background: Idiopathic osteonecrosis of the femoral head (ONFH) frequently occurs after liver transplantation (LT) because of lifelong administration of corticosteroids or immunosuppressants and often requires total hip arthroplasty (THA). This study examines patient characteristics and short-term outcomes of THA after LT.

Methods: We observed 9 hips in 7 patients who underwent THA from August 2015 to December 2017 for ONFH after LT (group L). Cementless implants were inserted in all hips. Medical records were retrospectively reviewed to reveal reasons for LT, type of donor, and period from LT to THA. Preoperative laboratory data, operative time, intraoperative blood loss, complication rates, and Harris Hip Score were compared with a control group of 27 cementless THAs in 27 patients with ONFH.

Results: Causative diseases were liver cirrhosis (n = 4), type B fulminant hepatitis (n = 1), congenital biliary atresia (n = 1), and iatrogenic biliary tract injury (n = 1). Four livers were from living donors and 3 from cadavers. Mean time from LT to THA was 10.4 (1-20) years. Preoperative blood test showed a significant decrease in platelet count (178 vs 268 [×10³/ml]) and rise in total bilirubin (1.1 vs 0.7 [mg/dL]) in group L. There was no significant difference in operative time (86 vs 100 [minutes]), but intraoperative blood loss (303 vs 163 [mL]) increased significantly in group L. There were no significant differences in complication incidence or Harris Hip Score between the 2 groups.

Conclusion: THA after LT requires caution because risks for bleeding increase. However, short-term outcomes appear to be equivalent to normal THA.

© 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
August 2015 and December 2017. During the study period, THA was performed on 9 hips in 7 patients with ONFH which developed after LT (group L). Group L consisted of 4 males and 3 females with a mean age of 58.4 years. A control group was recruited from patients who underwent unilateral cementless THA for all other ONFH patients during the same period (group C). Group C consisted of 27 ONFH patients (14 males and 13 females), with a mean age of 55.8 years. Background and operative characteristics of group L are shown in Table 1.

Surgical procedure

Surgery was performed with patients in the supine position using a minimally invasive anterior or anterolateral approach and with cementless implants in all patients. The surgical approach used in group L is shown in Table 1.

Survey items

Intraoperative data were obtained for each patient from medical records and our hospital-based computer system. Evaluated items included background characteristics, underlying disease for LT, type of donor liver, and duration from LT to THA. Preoperative laboratory tests (complete blood count, renal function, liver enzyme), operative time, intraoperative blood loss, incidence of perioperative complications, and the Harris Hip Score (HHS) were recorded preoperatively and postoperatively.

Statistical analysis

The Student’s t-test was used to compare parameters such as age, laboratory data, operation time, and intraoperative blood loss between the groups. The chi-square test was used to assess the incidence of perioperative complications. A P value of <.05 was considered statistically significant.

Results

The preoperative platelet count was significantly lower in group L (178,000/μL) than in group C (268,000/μL) (P < .01), and total bilirubin (T-Bil) level was significantly higher in group L (1.09 mg/dL) than in group C (0.73 mg/dL) (P < .05) (Table 2). The operative time was not significantly different between groups L (86 minutes) and C (100 minutes) (P > .05), but the blood loss was significantly greater in group L (303.6 mL) than in group C (163.4 mL) (P < .01) (Table 3). Concerning complications, deep venous thrombosis was observed in one patient from group L; in group C, intraoperative bone fracture was observed in one patient, deep venous thrombosis in 3, superficial infection in one, and cerebral infarction in one, but the incidence of complications did not differ between the 2 groups (P > .05) (Table 3). In both groups, implants were correctly placed, and no revision of THA was required. The mean HHS was 52.1 in group L and 56.7 in group C preoperatively and 82.9 in group L and 87.1 in group C at the time of final follow-up (mean 46.3 months). These were not significantly different at any time point (P > .05). When the operation was satisfactorily performed, both groups experienced favorable outcomes with no significant difference in improvement rate (Fig. 1).

Discussion

Patients with end-stage liver disease often suffer from severe coagulopathy [7]. Among patients with severe liver disorders, THA should be performed with caution because the rate of perioperative complications is high and outcomes are often poor [8]. However, there are few reports on the outcomes of THA in patients who have undergone cementless total hip arthroplasty for osteonecrosis of the femoral head after previous liver transplantation. Group C, control group who underwent cementless total hip arthroplasty for osteonecrosis of the femoral head for all other reasons.
surgery often differed among the study cohorts [9-15]. Studies involving only LT or THA are limited (Table 4).

In the case of THA after LT, hepatic functional reserve is the primary concern for surgery, as a low reserve may mean that surgery under general anesthesia aggravates liver function, resulting in liver failure and consequent deterioration of the general condition [17]. Parameters of hepatic functional reserve include platelet count and T-Bil levels; thus, these parameters should be evaluated before any surgery on patients who have undergone LT.

The risk of bleeding tendency is another major concern for THA after LT. The liver produces platelets and coagulation factors. As such, when hepatic function is decreased, the production of platelets and coagulation factors decreases concomitantly, resulting in a tendency to bleed readily [7]. Preoperative blood analysis in this study revealed that group L had decreased platelet counts, which may indicate decreased platelet production in the liver and mild liver impairment. Of all elective orthopedic operative procedures, THA is associated with a higher risk of blood loss as there is no effective method for controlling bleeding from the acetabular cancellous bone and femoral medullary cavity, which are exposed by acetabular reaming and femoral broaching. Quick implant placement is necessary to minimize the blood loss. In the present study, intraoperative blood loss was significantly greater, although not life-threatening, in group L despite operative times tending to be shorter in group L than in group C. The third problem for THA after LT is decreased bone quality. The liver plays a key role in bone metabolism. Bile is produced in the liver, concentrated in the gallbladder, and finally secreted into the duodenum via the bile ducts, where it has functions in fat absorption. A decrease in bile secretion leads to reduced absorption of fat-soluble vitamins. Among these, vitamins D and K are important for bone formation [18,19]. Therefore, abnormalities in the pathways between the liver and bile ducts result in decreased bone quality. In addition, vitamin D is activated in the liver and kidney, which does not occur in the case of liver impairment. The liver also synthesizes proteins that form the bone matrix; reduced liver function leads to decreased protein synthesis and reduced bone quality [20,21]. A decrease in bone quality related to liver impairment is referred to as hepatic osteodystrophy [22]. When orthopedic surgery is performed, decreased bone quality and changes in bone metabolism affect the long-term outcomes. Therefore, changes in bone metabolism should be evaluated and considered in surgical planning.

The final concern for THA is the increased susceptibility to infection of patients who have undergone LT. Immunosuppressants suppress humoral immunity, which increases the risk of postoperative complications [10,13,14]. In the present study, immunosuppressants such as tacrolimus were administered to all patients. Although no patient developed postoperative infection or wound troubles after THA, administration of immunosuppressants after organ transplantation must be continued throughout the patient’s life. As delayed infection is a risk, efforts should be made to prevent delayed infection in the entire body, including the respiratory and urinary tract systems, and to carry out early treatment as much as possible.

Aminata et al. [16] reported a study on 33 patients who underwent THA after LT between 2005 and 2014 and described the following preoperative criteria for THA: 1) preoperative hemoglobin >10 g/dL, 2) white blood cell count >5000/mL, and neutrophils >3000/mL, 3) aspartate aminotransferase and alanine aminotransferase <20 IU and T-Bil <1 mg/dL, 4) serum creatinine <1.7 mg/dL, 5) over 8 months since LT, 6) no intravenous steroid transferase <20 IU and T-Bil <1 mg/dL, 4) serum creatinine <1.7 mg/dL, 5) over 8 months since LT, 6) no intravenous steroid administration, 7) more than 1 week between operations in bilateral cases, 8) the recipient is liver tolerant of general anesthesia, and 9) continuation of immunosuppression therapy [16]. In the present study, almost all patients of group L fulfilled these criteria, despite slightly high T-Bil levels. Although there were 2 patients who underwent simultaneous bilateral THA operations at our hospital and these required allogenic blood transfusion, they developed no complications during the perioperative period. Therefore, when the patient condition permits and indications are carefully determined, simultaneous bilateral operations may also be possible.

The limitation of this study is that the follow-up period is 2-5 years, so the long-term results are unknown.

### Table 4

| Author            | Transplanted organs | Surgeries         | Clinical results                  |
|-------------------|---------------------|-------------------|-----------------------------------|
| Lezitsky et al.   | Liver               | 8 TKA, 3         | Uneventful                        |
| 2003 [11]         |                     | THA, 1 TAA       |                                   |
| Orban et al.      | Liver, kidney       | 4 TKA            | Uneventful, cement implant is     |
| 2012 [9]          |                     |                  | recommended                        |
| Aminata et al.    | Liver               | 33 TKA           | Blood loss increased              |
| 2012 [16]         |                     |                  |                                   |
| Ledford et al.    | Heart, lung, kidney | 55 TKA, 21       | Reoperation, renal failure,       |
| 2014 [13]         |                     | TK A,           | Reoperation, infection in THA      |
| Klement et al.    | Heart, lung, kidney | 3334 TKA         | Reoperation, fracture, infection   |
| 2016 [10]         |                     |                  | increased                          |
| Chalmers et al.   | Heart, lung, kidney | 136 TKA          | Mortality, reoperation, infection  |
| 2016 [14]         |                     |                  | increased                          |

TAA, total ankle arthroplasty; THA, total hip arthroplasty; TKA, total knee arthroplasty.

### Conclusions

THA performed after LT requires careful attention because of a possible increased risk of intraoperative blood loss, although this blood loss is manageable by autologous or allogenic blood transfusion. The context of prior LT does not appear to increase the risk of perioperative complications such as intraoperative bone fractures or infections in THA. Concerning clinical results, the improvement in HHS does not appear to be affected by previous LT in patients with ONFH. Our results suggest that THA after LT must be carefully planned and managed but achieves similar outcomes to general THA if the patient’s general condition permits surgery. Longer follow-up should be carried out for patients undergoing...
THA after LT, and annual changes in bone responses and implant loosening should be carefully monitored.

**Conflict of Interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

**Acknowledgment**

Funding: The authors would like to thank Ryoichi Izumida of Edogawa Hospital for Publication Support.

**References**

[1] Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation 2018;102:727.

[2] Li H, He JW, Fu BS, et al. Immunosuppressant-related hip pain after orthotopic liver transplant. Exp Clin Transplant 2013;11(1):32.

[3] Li H, Zhang J, He JW, et al. Symptomatic osteonecrosis of the femoral head after adult orthotopic liver transplantation. Chin Med J (Engl) 2012;125:2422.

[4] Takao M, Sakai T, Nishii T, Yoshikawa H, Takahara S, Sugano N. Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients. Rheumatol Int 2011;31(2):165.

[5] Jadlowiec CC, Taner T. Liver transplantation: current status and challenges. World J Gastroenterol 2016;22:4438.

[6] Soyama A, Eguchi S, Egawa H, et al. Liver transplantation in Japan. Liver Transpl 2016;22(10):1401.

[7] Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147.

[8] Tiberi 3rd JV, Hansen V, El-Abbadi N, Bedair H. Increased complication rates after hip and knee arthroplasty in patients with cirrhosis of the liver. Clin Orthop Relat Res 2014;472:2774.

[9] Orban H, Adam R, Orban C. Arthroplasty risk after kidney or liver transplant. Chirurgia 2012;107:664.

[10] Klement MR, Penrose CT, Bala A, Wellman SS, Bolognesi MP, Seyler TM. How do previous solid organ transplant recipients fare after primary total knee arthroplasty? J Arthroplast 2016;31:609.

[11] Levitsky J, Te HS, Cohen SM. The safety and outcome of joint replacement surgery in liver transplant recipients. Liver Transpl 2003;9:373.

[12] Vergidis P, Lesnick TG, Kremers WK, Razonable RR. Prosthetic joint infection in solid organ transplant recipients: a retrospective case-control study. Transpl Infect Dis 2012;14:380.

[13] Ledford CK, Watters TS, Wellman SS, Attarian DE, Bolognesi MP. Risk versus reward: total joint arthroplasty outcomes after various solid organ transplantations. J Arthroplast 2014;29:1548.

[14] Chalmers BP, Ledford CK, Statz JM, et al. Survivorship after primary total hip arthroplasty in solid-organ transplant patients. J Arthroplast 2016;31:2525.

[15] Cavanaugh PK, Chen AF, Rasouli MR, Post ZD, Orozco FR, Ong AC. Total joint arthroplasty in transplant recipients: in-hospital adverse outcomes. J Arthroplast 2015;30:840.

[16] Aminata I, Lee SH, Chang JS, et al. Perioperative morbidity and mortality of total hip replacement in liver transplant recipients: a 7-year single-center experience. Transplantation 2012;94:1154.

[17] Anesthesics, general. In: Livertoxicology: clinical and research information on drug-induced liver injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

[18] Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003;7:901.

[19] Azuma K, Ouchi Y, Inoue S. Vitamin K: novel molecular mechanisms of action and its roles in osteoporosis. Geriatri Gerontol Int 2014;14(1):1.

[20] Chi-Tsu CE, Lazár M, Olariu C, et al. Hepatic osteodystrophy: a global (Re) view of the problem. Acta Clin Croat 2017;56:512.

[21] Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M. Hepatic osteodystrophy. Clin Cases Miner Bone Metab 2014;11:185.

[22] Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001;33:301.